Tags : Momelotinib

Sierra Oncology Amends its Asset Purchase Agreement with Gilead for

Shots: As per the amended agreement, Gilead will reduce the royalty rates of Momelotinib & eliminates milestone payments in exchange for becoming a stockholder in Sierra, following the closing of Sierra’s qualified financing. In Aug’2018, Sierra acquired Gilead’s Momelotinib for $3M up front, $195M milestones and royalties on sales Additionally, Sierra and Gilead Sciences would […]Read More

Sierra Oncology Acquires Gilead’s Momelotinib to Treat Myelofibrosis for ~$198M

Shots:  Sierra will pay $3M upfront and ~$195M milestone payments to Gilead and additional royalties from mid-teen-to-high-twenties on net sales Sierra will continue all currently ongoing clinical studies with Momelotinib following a transition period Momelotinib (a JAK 1/2 and ACVR1 Inhibitor) is in Phase III, has being administered to ~1200 patients, since 2009, and is […]Read More